• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
Standard & Poors 500
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Verrica Pharmaceuticals Inc. - Common Stock (NQ:VRCA)

3.830 +0.200 (+5.51%)
Delayed Quote Updated: 4:00 PM EDT, Oct 22, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 109,896
Open 3.500
Bid (Size) 3.050 (100)
Ask (Size) 3.900 (200)
Prev. Close 3.630
Today's Range 3.500 - 4.170
52wk Range 3.280 - 9.821
Shares Outstanding 41,957,197
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Verrica Pharmaceuticals Announces Achievement of Milestones Unlocking Access to the Full $27.5 Million of Non-Dilutive Growth Capital Under Credit Facility
Today 8:00 EDT
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Verrica Pharmaceuticals to Present New YCANTH® Data Analysis at Two Upcoming Dermatology Conferences
September 30, 2026
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire

Performance

52-Week Range 61.0% below 52-week high
3.830
3.2852W Low 9.8252W High
1 Week 3.0% below 1-week high
3.301W Low 3.951W High

Verrica Pharmaceuticals Inc. - Common Stock (VRCA) traded between $3.28 and $9.82 over the past 52 weeks and last traded at $3.83, 61.0% below its 52-week high. Over the past week it ranged between $3.30 and $3.95.

Past 12 Months
+1.3%
-14.7%
-32.8%
-41.1%
-53.9%
-5.2%
1W +$0.05
1M -$0.66
3M -$1.87
6M -$2.67
YTD -$4.47
1Y -$0.21

VRCA was -5.2% over the past year, -41.1% over six months, -53.9% year to date, +1.3% in the last week.

12 Months vs Market
VRCA
-5.2%
DIA
+12.5%
SPY
+13.8%
QQQ
+15.2%
IWM
+12.0%

Over the past 12 months VRCA returned -5.2% versus DIA (Dow) +12.5%, SPY (S&P 500) +13.8%, QQQ (Nasdaq 100) +15.2% and IWM (Russell 2000) +12.0%.

Volume & Liquidity 1.59× 3-mo avg
Today 109,896 3-mo avg 68.9K
1W
79.6K
1M
53.5K
3M
68.9K
6M
62.8K
YTD
89.0K
1Y
122.8K

VRCA most recently traded 109,896 shares against a 3-month average daily volume of 68.9K.

More News

Read More
News headline image
Verrica Pharmaceuticals to Present YCANTH® and VP-315 Data at Two Upcoming Dermatology Conferences
September 10, 2026
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Verrica Pharmaceuticals to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
September 08, 2026
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Verrica Pharmaceuticals Announces Completion of Enrollment in First Pivotal Phase 3 Trial (COVE-2) Evaluating YCANTH® for the Treatment of Common Warts, with Topline Data Expected Q1 2027
August 27, 2026
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
Verrica Pharmaceuticals (NASDAQ:VRCA) Q1 Results Beat Revenue Estimates as Pipeline Progress and Record Demand Drive Positive Momentum ↗
May 12, 2026
Via Chartmill
News headline image
Verrica (VRCA) Q2 2026 Earnings Call Transcript ↗
August 13, 2026
Via The Motley Fool
Topics Earnings
News headline image
Verrica Pharmaceuticals Q2 Earnings Call Highlights ↗
August 07, 2026
Via MarketBeat
Topics Earnings
News headline image
Verrica Pharmaceuticals Reports Second Quarter 2026 Financial Results
August 06, 2026
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Verrica Pharmaceuticals Closes Credit Facility For Up To $27.5 Million in Non-Dilutive Growth Capital
August 06, 2026
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Verrica Pharmaceuticals to Report Second Quarter 2026 Financial Results and Provide a Corporate Update on August 6, 2026
July 30, 2026
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel
July 21, 2026
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Verrica Pharmaceuticals Announces First U.S. Patient Dosed in the Second Pivotal Clinical Trial (COVE-3) of its Phase 3 Program Evaluating YCANTH® (VP-102) for the Treatment of Common Warts
June 22, 2026
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Verrica Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference
May 28, 2026
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Verrica (VRCA) Q1 2026 Earnings Transcript ↗
May 13, 2026
Via The Motley Fool
News headline image
Verrica Pharmaceuticals to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ
May 13, 2026
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Verrica Pharmaceuticals Q1 Earnings Call Highlights ↗
May 12, 2026
Via MarketBeat
Topics Earnings
News headline image
Verrica Pharmaceuticals Reports First Quarter 2026 Financial Results
May 12, 2026
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Verrica Pharmaceuticals Announces Upcoming Presentation of Phase 2 Data Highlighting the Potential Abscopal Effects of VP-315 in the Treatment of Basal Cell Carcinoma at the 2026 Society for Investigative Dermatology (SID) Annual Meeting
May 05, 2026
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Verrica Pharmaceuticals to Report First Quarter 2026 Financial Results and Provide a Corporate Update on May 12, 2026
May 05, 2026
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Verrica Pharmaceuticals Announces Acceptance of Late-Breaking Abstract Highlighting Potential Abscopal Effect of VP-315 for the Treatment of Basal Cell Carcinoma at the Upcoming 2026 Society for Investigative Dermatology Annual Meeting
April 09, 2026
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Verrica Pharmaceuticals to Participate in the 25th Annual Needham Virtual Healthcare Conference
April 06, 2026
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
VRCA Investors Have the Opportunity to Join Investigation of Verrica Pharmaceuticals Inc. with the Schall Law Firm
March 20, 2026
From The Schall Law Firm
Via Business Wire
News headline image
VRCA Investor News: Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of Verrica Pharmaceuticals Inc. – VRCA
March 20, 2026
From The Rosen Law Firm, P.A.
Via Business Wire
News headline image
Verrica Pharmaceuticals Investor News: Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of Verrica Pharmaceuticals Inc. – VRCA
March 19, 2026
From The Rosen Law Firm, P.A.
Via Business Wire

Frequently Asked Questions

Is Verrica Pharmaceuticals Inc. - Common Stock publicly traded?
Yes, Verrica Pharmaceuticals Inc. - Common Stock is publicly traded.
What exchange does Verrica Pharmaceuticals Inc. - Common Stock trade on?
Verrica Pharmaceuticals Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Verrica Pharmaceuticals Inc. - Common Stock?
The ticker symbol for Verrica Pharmaceuticals Inc. - Common Stock is VRCA on the Nasdaq Stock Market
What is the current price of Verrica Pharmaceuticals Inc. - Common Stock?
The current price of Verrica Pharmaceuticals Inc. - Common Stock is 3.830
When was Verrica Pharmaceuticals Inc. - Common Stock last traded?
The last trade of Verrica Pharmaceuticals Inc. - Common Stock was at 10/22/26 04:00 PM ET
What is the market capitalization of Verrica Pharmaceuticals Inc. - Common Stock?
The market capitalization of Verrica Pharmaceuticals Inc. - Common Stock is 160.70M
How many shares of Verrica Pharmaceuticals Inc. - Common Stock are outstanding?
Verrica Pharmaceuticals Inc. - Common Stock has 161M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap